Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Multinationals Start 2021 Empty Handed In China National Reimbursement Race

China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.

Commercial Market Access

TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.

BioPharmaceutical Immune Disorders

Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

Coronavirus COVID-19 Vaccines

Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines

Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.

Coronavirus COVID-19 Vaccines

Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva

Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.

Deals Renal

Moving Cell And Gene Therapies Into Chronic Conditions Depends On Durability, Safety

Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.

Gene Therapy Regenerative Medicine

Roche Strikes Reality Note For Production Of Regeneron-Partnered COVID-19 Antibody Cocktail

Roche Pharma CEO Bill Anderson is excited about the prospects for REGN-COV2 but with the company and Regeneron possibly producing two million doses per year by the end of Q1 2021, meeting demand worldwide will be an impossible task.

Coronavirus COVID-19 Manufacturing

After Another NICE No, Will It Be Third Time Lucky For J&J's Spravato?

The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.

Market Access Neurology

Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access

Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.

China Commercial
See All
UsernamePublicRestriction

Register